CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT

Cosmo Feilding Mellen will present at the H.C. Wainwright 2nd Annual Psychedelics Conference, taking place virtually on December 6th, 2021, and the Stifel 2nd annual conference The Future of Healthcare, taking place virtually on December 8th, 2021.

Oxford, United Kingdom – 3 November 2021 - Beckley Psytech, a privately owned, clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has today announced the appointment of Frank Wiegand MD. PhD. as Chief Medical Officer.

Cosmo Feilding Mellen, Chief Executive Officer, to present at the Jefferies 2021 London Healthcare Conference, taking place in-person and virtually from 16th to 19th November, 2021.

Phase 1 trial is evaluating the safety and tolerability of a novel formulation of intranasal 5-MeO-DMT Study will measure detailed pharmacokinetics and metabolism of 5-MeO-DMT in healthy volunteers Preliminary data, expected H1 2022, to support Phase 2 study designs investigating the use of 5-MeO-DMT in treatment resistant depression (TRD) and other neuropsychiatric indications

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA) Data expected in early 2022 SUNHA, a rare and debilitating headache condition, is estimated to affect 40,000 patients in US and Europe

Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer with immediate effect.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare and debilitating headache condition.